Carlos García Girón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos García Girón has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Blanca Pilar Galindo Torres
Servicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain
2 shared publications - María Isabel Adiego Leza
Servicio Otorrinolaringología, Hospital Universitario Miguel Servet, Zaragoza, Spain
2 shared publications - Miguel Grijalba Uche
Universidad Isabel I
2 shared publications - Patricia Saiz-Lopez
Servicio Anatomía Patológica, Hospital Universitario de Burgos, Burgos, Spain
2 shared publications - Raquel Alcaraz Ortega
Unidad de Investigación, Hospital Universitario de Burgos, Burgos, España
2 shared publications Blanca Pilar
1 shared publication
Latest Publications
- 27 July 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (10) , 6729-6739
Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.
- 27 July 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (10) , 6729-6739
Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.
- 6 February 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (8) , 3399-3409
New evidence for miRNA testing in head and neck squamous cell cancer patients
Purpose Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer. Methods/Patients An observational, longitudinal, prospective, analytical study was conducted, with a case–control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients. Results Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R2 = 0.634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR-374b-5p, with advanced stage (p = 0.005). Conclusion Our findings suggest that the evaluation of certain miRNAs’ expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.
- 6 February 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (8) , 3399-3409
New evidence for miRNA testing in head and neck squamous cell cancer patients
Purpose Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer. Methods/Patients An observational, longitudinal, prospective, analytical study was conducted, with a case–control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients. Results Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R2 = 0.634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR-374b-5p, with advanced stage (p = 0.005). Conclusion Our findings suggest that the evaluation of certain miRNAs’ expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.